Stoke Therapeutics Stock Price, News & Analysis (NASDAQ:STOK)

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Stoke Therapeutics (NASDAQ:STOK) posted its quarterly earnings results on Wednesday, August, 14th. The company reported ($1.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.96) by $0.58. View Stoke Therapeutics' Earnings History.

Stoke Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Stoke Therapeutics.

4 equities research analysts have issued twelve-month target prices for Stoke Therapeutics' shares. Their forecasts range from $34.00 to $44.00. On average, they anticipate Stoke Therapeutics' share price to reach $37.67 in the next year. This suggests a possible upside of 68.8% from the stock's current price. View Analyst Price Targets for Stoke Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stoke Therapeutics.

Media coverage about STOK stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Stoke Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Stoke Therapeutics.

Stoke Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totalling 635,900 shares, an increase of 78.2% from the August 30th total of 356,800 shares. Based on an average trading volume of 188,200 shares, the days-to-cover ratio is presently 3.4 days. Approximately 4.1% of the shares of the stock are short sold. View Stoke Therapeutics' Current Options Chain.

Some companies that are related to Stoke Therapeutics include Emergent Biosolutions (EBS), Alkermes (ALKS), Genmab A/S (GMAB), HUTCHISON CHINA/S (HCM), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), Arena Pharmaceuticals (ARNA), Biohaven Pharmaceutical (BHVN), PTC Therapeutics (PTCT), Ra Pharmaceuticals (RARX), BridgeBio Pharma (BBIO), Intercept Pharmaceuticals (ICPT), Amicus Therapeutics (FOLD), Xencor (XNCR) and Ligand Pharmaceuticals (LGND).

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Aeglea Bio Therapeutics (AGLE), Akero Therapeutics (AKRO), Arena Pharmaceuticals (ARNA), Caladrius Biosciences (CLBS), Endo International (ENDP), Exelixis (EXEL), Innoviva (INVA), Ionis Pharmaceuticals (IONS), Theravance Biopharma (TBPH) and Amneal Pharmaceuticals (AMRX).

(STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Stoke Therapeutics' lock-up period expires on Monday, December 16th. Stoke Therapeutics had issued 7,891,110 shares in its initial public offering on June 19th. The total size of the offering was $142,039,980 based on an initial share price of $18.00. After the expiration of Stoke Therapeutics' lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of STOK stock can currently be purchased for approximately $22.31.

Stoke Therapeutics has a market capitalization of $729.98 million. Stoke Therapeutics employs 44 workers across the globe.View Additional Information About Stoke Therapeutics.

The official website for Stoke Therapeutics is http://www.stoketherapeutics.com/.

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at 781-430-8200 or via email at [email protected]